

LIBERIA

Support for Human Papillomavirus Vaccine (HPV)
This Decision Letter sets out the Programme Terms of a Programme

1.	Country:	Liberia							
٠.	Country.	Liberia							
2.	Vaccine gra	nt number:		19-LBR-08f	-Y, 1920-LBI	R-19b-X			
3.	Date of Deci	sion Letter:		30-Sep-201	9				
4.	Date of the Partnership Framework			Agreement: 19 August 2			2013		
5.	Programme title: New Vaccine			e Support (NVS), HPV, Routine					
6.	Vaccine type: Hu		Human Pap	Human Papillomavirus Vaccine					
7.	Requested product presentation and formulation of vaccine:								
	HPV Quadrivalent, 1 dose(s) per vial, LIQUID								
8.	Programme								
9.	Programme	me Budget (indicative): ² (subject to the terms of the Partnership Framework Agreement, if applicable)							
		2019	2020	2021	2022	2023	2024	Total ²	
	Programme Budget (US\$)	584,500	585,000	-	-	-	-	1,169,500	
10.	Vaccine introduction grant								
	Approval								
		Year Grant Numb			Amount (US\$)				
		2019 19-LBR-08f-Y		153,473					
	Disbursement								
		Disburser	nent date	Amoun	nt (US\$)				
		17 Janua	ry, 2019		152,870				
11.	Product swi	tch grant							
	-								
	Not applicable								
40	In all a attract A		-1- 2						
12.	. Indicative Annual Amounts: ³ (subject to the terms of the Partnership Framework Agreement, if applicable)								
	Type of supplies to be purchased with Gavi funds		2019		2020		2021		

 ¹ This is the entire duration of the programme.
 ² This is the total amount endorsed by Gavi for the entire duration of the programme.
 ³ This is the amount that Gavi has approved.



Number of vaccine doses	128,400	128,400	-
Annual Amounts (US\$)	584,500	585,000	-

UNICEF. The Country shall release its co-financing payments each year 13. Procurement agency:

to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	6,000		-	-	-
Number of AD syringes	-	1	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	26,551	-	-	-	-
Total co-financing payments (US\$) (including freight)	27,000	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
 Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

Signed by,

On behalf of Gavi

Thabani Maphosa,

Managing Director, Country Programmes

30-Sep-2019